Relay Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Relay Therapeutics

02/05/2025 22:12

Relay Therapeutics Inc RLAY.OQ RLAY.O is expected to show a fall in quarterly revenue when it reports  results on May 5 for the period ending March 31 2025

The Cambridge Massachusetts-based  company is expected to report a 99.9% decrease in revenue to $10 thousand from $10.01 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Relay Therapeutics Inc is for a loss of 49 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 1.6% in the last three months. ​

Wall Street's median 12-month price target for Relay Therapeutics Inc is $16.50​, above​ its last closing price of $3.29. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.56
-0.56
-0.45
Beat
19.9
Sep. 30 2024
-0.76
-0.77
-0.63
Beat
17.9
Jun. 30 2024
-0.73
-0.73
-0.69
Beat
5.8​
Mar. 31 2024
-0.69
-0.70
-0.62
Beat
12
​​Dec. 31 2023
-0.69
-0.73
-0.67
Beat
8
Sep. 30 2023
-0.82
-0.83
-0.54
Beat
35​
Jun. 30 2023
-0.84
-0.82
-0.81
Beat
0.7
Mar. 31 2023
-0.66
-0.69
-0.78
Missed
-12.8

This summary was machine generated May 2 at 21:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)